β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the predominant theory in AD pathogenesis, wherein this enzyme generates Aβ, and currently, multiple clinical trials are targeting BACE1 for controlling AD progression [11]. Here, BACE1 is linked to Alzheimer disease.